| Interleukin 15 in cell-based cancer immunotherapy Y Zhou, T Husman, X Cen, T Tsao, J Brown, A Bajpai, M Li, K Zhou, ... International Journal of Molecular Sciences 23 (13), 7311, 2022 | 36 | 2022 |
| Engineering induced pluripotent stem cells for cancer immunotherapy Y Zhou, M Li, K Zhou, J Brown, T Tsao, X Cen, T Husman, A Bajpai, ... Cancers 14 (9), 2266, 2022 | 26 | 2022 |
| Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering D Lee, ZS Dunn, W Guo, CJ Rosenthal, NE Penn, Y Yu, K Zhou, Z Li, ... Nature Communications 14 (1), 6942, 2023 | 3 | 2023 |
| Effect of time spent on active learning on exam performance: A controlled case study on a course with different instructors but identical teaching materials X Cen, RJ Lee, C Contreras, MT Owens, J Maloy bioRxiv, 2022.09. 01.506238, 2022 | 2 | 2022 |
| Minimally Invasive Preclinical Monitoring of the Peritoneal Cavity Tumor Microenvironment ZS Dunn, YR Li, Y Yu, D Lee, A Gibbons, JJ Kim, TY Zhou, M Li, ... Cancers 14 (7), 1775, 2022 | 2 | 2022 |
| The YAP/TAZ antagonist, PTPN14, stabilizes SMAD4 through direct interactions in endothelial cells: Implications for Hereditary Hemorrhagic Telangiectasia O Mamai, DT Beleford, M Taylor, S Basu, X Cen, S Trilok, J Zhang, ... bioRxiv, 2021.09. 29.462397, 2021 | 1 | 2021 |
| Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy YR Li, Y Zhou, J Yu, Y Zhu, D Lee, E Zhu, Z Li, YJ Kim, K Zhou, Y Fang, ... Molecular Therapy, 2024 | | 2024 |
